🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — April 09, 2026

The 50 filings for USA S&P 500 Healthcare stream reveal limited direct healthcare activity amid a surge in proxy statements (20+ DEF 14A/DEFA14A) for May 2026 AGMs, signaling routine governance with neutral sentiment across sectors. Healthcare standouts include IDEAYA Biosciences' positive AstraZeneca collaboration for Phase 1 SCLC trial and Forte Biosciences' $150M equity raise at $26.27/share for clinical development, contrasting Ensysce Biosciences' bearish going concern warning with cash runway only to Q2 2026 and Nasdaq delisting risk by Aug 24, 2026. Period-over-period data is sparse but highlights Tilly's mixed FY2026 results: sales -2.8% YoY to $554M but gross margins +340bps to 29.7%, narrowing net loss to $17M from $46M. Non-healthcare filings dominate with bullish developments like CoreWeave's $21B Meta cloud deal through 2032, Abra's $750M SPAC merger with BTC optimism to $100K, and PG&E's doubled $0.20 dividend plus 9%+ EPS growth guidance. Capital allocation trends favor debt reduction (Six Flags property sale) and buybacks (News Corp $1B program), while forward catalysts cluster in May AGMs and Forte's Apr 10 close. Portfolio-level, biotech shows fundraising conviction amid cash pressures, implying selective M&A/partnership alpha in oncology/regenerative therapies.

22 high priority 28 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 09, 2026

Across 50 DEF 14A filings for US SEC-listed companies, the dominant theme is routine governance with votes on director elections (majority/plurality), advisory say-on-pay (high prior approvals like NOV's 97%), equity incentive plan amendments/approvals (e.g., Ellington 2026 EIP, PHINIA), and 2026 auditor ratifications (Deloitte/PwC/EY prevalent), ahead of clustered May 2026 virtual AGMs (45/50 virtual). Positive sentiment in 12 filings (24%) underscores 2025 outperformance: avg revenue growth ~11-15% YoY where reported (Instacart GTV +11%, Orders +15%; MasTec Clean Energy rev to $4.7B from $300M), TSR leaders like PHINIA 33% vs S&P 600 6%, capital returns (Trinity $170M dividends/buybacks, PHINIA 20% shares repurchased, PG&E dividend doubled to $0.20/share), and ROE peaks (Trinity 24.4%). Mixed/negative in 5 (10%): NOV rev -1% YoY/$8.74B, EBITDA -7%/$1.03B; Instacart NI -2% YoY/$447M; Willow Lane unremediated material weaknesses in ITGC/segregation persisting into 2026. Board refreshment common (Amazon Keith Alexander retiring, Illumina 3 retirements), with 80%+ independence (Piper 8/10, all committees independent at Am Public Ed), concentrated ownership (Table Trac insiders 30.33%, chairman 25.51%). Portfolio implications: Bullish alignment of comp to performance in industrials/healthcare; watch say-on-pay as conviction gauge; no broad insider selling, high CEO ownership (Kinsale $300M); alpha in capital allocators amid clustered May catalysts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 09, 2026

The IPO Pipeline stream reveals a surge in S-1 filings with three new registrations (AMASS Brands, RMX Industries, BioLargo) signaling heightened public market activity on April 8-9, 2026, alongside follow-on and combination filings from Aptera, JCP&L, and BioLargo duplicate. Period-over-period trends show modest expense control in JCP&L (affiliated opex down 1.7% YoY to $116M in 2025, 3.3% in 2024) contrasting dilution pressures in BioLargo (shares outstanding +5.3% YoY to 317M) and declining option intrinsic value (-22.6% to $1.67M). Mixed sentiments dominate (3/6 filings) due to compensation inconsistencies in AMASS (CEO salary +20% to $200k but flat total comp, COO +big on options, zero bonuses), pre-production risks in Aptera, and customer concentration/past-due receivables in BioLargo. No insider trading or capital allocation shifts noted across filings, but post-listing equity grants in AMASS and warrant exercises in Aptera highlight near-term dilution risks. Portfolio-level pattern: 4/6 filings emphasize governance/equity plans amid limited financial disclosure, implying early-stage IPO prep with high materiality (avg 8/10). Market implication: Investors should monitor for pricing catalysts, as neutral/mixed tones suggest cautious entry points in nascent listings.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — April 09, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include multiple Indian insolvencies (Kallam Textiles x3, Vas Infrastructure, Pradeep Metals amalgamation), signaling distress in textiles/infrastructure sectors, contrasted by robust M&A/SPAC activity (Whitestone REIT $1.7B takeover at 12.2% premium, Terra Quantum $3.25B LOI, Abra $750M SPAC). Period-over-period trends show mixed financials: revenue declines averaging -16% YoY in consumer (Beyond Meat -15.6%, Resources Connection -16.6% Q3), offset by growth outliers like Healthy Extracts +45% YoY revenue; margins compressed sharply (Beyond Meat gross margin -10% to 2.8%). US SEC filings highlight biotech/pharma positives (C4 Therapeutics $1B+ Roche collab milestones, Forte Biosciences $150M offering), while Indian firms show capital allocation like TCS ₹31 final dividend recommendation. Critical implications: Avoid Indian distressed names, pursue SPAC/takeover plays for liquidity events, monitor Q2 catalysts amid 5+ earnings/prelim results. Portfolio pattern: 8/50 filings bearish distress (insolvencies), 12/50 bullish M&A/capital raises, with no insider trading patterns but exec transitions signaling stability.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 09, 2026

Across 24 filings in the Financial Results & Earnings stream, overarching themes reveal a bifurcated market with 14/24 companies reporting YoY revenue declines averaging -12.5% (e.g., Beyond Meat -15.6%, KB Home -22.6%, Lennar -13.3%), driven by housing weakness and consumer pullback, while 10 showed growth averaging +18% (e.g., Healthy Extracts +45%, WD-40 +10.7%, Worthington Enterprises +24.4%). Margin compression affected 9/24 firms (avg -250 bps, e.g., Simply Good Foods impairment), but loss narrowing was common in 12 cases (e.g., Resources Connection net loss -78% YoY, BlackBerry swing to profit). Capital allocation leaned defensive with buybacks/dividends in homebuilders (KB Home $50M repurchases, Lennar $270M), but cash burn rose in 8 microcaps. Homebuilding sector dragged portfolios (revenue -18% avg), contrasting resilient industrials (Worthington +20% sales). SPACs face redemption risks (IX Acquisition trust -52%). Implications: Trim housing exposure, seek turnaround alpha in mixed-sentiment small caps with improving losses.

24 high priority 24 total filings
· daily

US SEC Trading Suspension Halt Orders — April 09, 2026

A cluster of 5 Nasdaq-related regulatory actions highlights acute distress among small-cap US-listed companies, with Actelis Networks facing immediate delisting on April 10, 2026, after a failed 1-for-10 reverse split on November 18, 2025, marking the most severe outcome. Three companies (Gossamer Bio, FibroGen, Newton Golf) received deficiency notices for bid price, assets/revenue, and stockholders' equity failures, respectively, with 45-180 day compliance windows through October 2026, while Beyond Meat resolved a late 10-K filing without disruption. No enriched period-over-period financial trends show growth; instead, implied YoY deteriorations (e.g., FibroGen revenue shifted to discontinued ops for 2024-2025) underscore weak fundamentals driving non-compliance. Biotech firms (Gossamer, FibroGen) represent 40% of cases, signaling sector-specific pressures amid low bid prices and asset shortfalls. Portfolio-level implications include liquidity erosion, OTC transitions, and heightened short opportunities, with no bullish capital allocation or insider buying patterns evident across filings.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 09, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, a bifurcated picture emerges: 6 companies face acute Nasdaq listing risks (delistings, bid price, equity, assets/revenue deficiencies), signaling heightened distress in small-cap biotech/tech sectors, while 12 feature capital raises (offerings, notes, ATM) and 5 M&A/sale deals providing liquidity relief. No explicit YoY/QoQ revenue declines or margin compressions noted, but reverse splits in 3 firms (Actelis prior, Mobix, Quince) and dilutive financings (e.g., Intrusion $3.2M note, Prairie warrant dilution) highlight cash burn pressures; positive offsets include REIT acquisitions at 12-26% premiums and biotech partnerships unlocking $1B+ milestones. Portfolio-level trends show 70% neutral/positive sentiment, with distress concentrated in Nasdaq-deficient firms (avg materiality 9/10); forward catalysts cluster in Q2-Q3 2026 (closings, compliance deadlines). M&A (e.g., Whitestone $1.7B, Assertio $125M) offers exit premiums amid distress, but delisting risks (Actelis immediate) demand vigilance. Implications: Opportunistic M&A in REITs/energy, avoid Nasdaq-at-risk biotechs unless compliance plans succeed.

31 high priority 31 total filings
· daily

US Executive Officer Management Changes SEC — April 09, 2026

Across 31 filings in the USA Executive & Director Changes stream, a dominant theme is proactive leadership realignments in healthcare and biotech (12/31 companies), with 70% involving new appointments of experienced executives to drive growth amid revenue trends showing mixed but mostly stable YoY performance (e.g., Buckle +8.2% YoY sales, Orthofix +1.6% YoY Q1 net sales). Period-over-period data highlights outperformance in retail (Buckle 9-week sales +8.5% YoY) contrasting softer medtech growth (Treace Q1 rev flat QoQ but FY26 guidance narrowed to $202-212M, Orthofix pro forma +3.8% YoY). Critical developments include high-materiality transitions like BayCom's full C-suite handover (materiality 9/10) and Green Stream's complete board/officer replacement (negative sentiment), alongside positive board additions in tech/defense (e.g., SAIC, AeroVironment). No widespread insider selling but equity grants and bonuses signal retention efforts (e.g., Adial RSAs to CEO/CFO). Portfolio-level patterns show 18 positive/neutral appointments vs. 7 departures/resignations, implying sector conviction in scaling operations; watch for execution risks in transitions. Overall market implication: Bullish for healthcare scaling plays, cautious on small-cap turnarounds with governance shifts.

31 high priority 31 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 09, 2026

Across 31 filings on USA Board Room Changes from April 9, 2026, a dominant theme is proactive board and executive refreshes, with 18 positive appointments in healthcare/biotech (e.g., OptimizeRx, Cardiff Oncology, Pulse Biosciences) bringing AI, M&A, and scaling expertise amid sector growth. Leadership transitions show mixed sentiment: 9 neutral retirements/resignations (e.g., Valmont CFO, Colgate Legal), 4 negative/mixed (e.g., Green Stream mass resignation, BayCom founder exits), but offset by sales beats like Buckle +8.2% YoY 5-week sales and +7.0% comps, Orthofix Q1 +1.6% YoY net sales (pro forma +3.8%), and Treace Q1 $47M-$47.2M revenue with cash up $3.5M QoQ. No widespread insider selling, but equity grants signal retention (e.g., Cardiff 486k options to new CFO). Guidance largely stable: Orthofix reaffirms FY2026 $850-860M sales (+5.5% pro forma CC midpoint), Treace narrows to $202-212M (slight raise at low end). Portfolio-level: Healthcare/medtech outliers with Q1 growth despite churn; retail outperforms; financials face transition risks but clean balance sheets. Implications: Bullish for expertise-driven turnarounds, watch medtech catalysts like Orthofix May 5 earnings.

31 high priority 31 total filings
· daily

US Merger & Acquisition SEC Filings — April 09, 2026

The 11 filings reveal surging SPAC-driven M&A activity, with 4 major business combination announcements (Mountain Lake $3.25B quantum, Constellation $571M lithium, Fifth Era strategic metals, Willow Lane proxy risks) targeting high-tech and critical minerals, signaling strong investor appetite for strategic assets amid 2026 deal rebound. Completed transactions dominate positives: Sealed Air's $10.3B take-private at $42.15/share delisting and Ovintiv's $3.0B Anadarko divestiture funding debt target achievement and returns. Neutral unit separations (Paloma, GalaxyEdge) enhance liquidity, while extensions (byNordic 9th to May 12), Nasdaq issues (DT Cloud Star <400 holders), and control weaknesses (Boost Run unremediated into 2026) highlight SPAC persistence risks. No uniform PoP financial trends across filings, but aggregate deal valuations exceed $17B, with positive sentiment in 6/11 (55%) vs negative/mixed in 3/11. Portfolio implications: Bullish de-SPAC catalysts in quantum/lithium/metals; caution on SPAC delays/compliance; energy firms optimizing balance sheets for returns.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 09, 2026

Overnight SEC filings from April 8-9, 2026, reveal a dominant proxy season buildup with 10+ companies (e.g., Piper Sandler, Solid Power, Amazon) scheduling virtual annual meetings around May 20, 2026, urging FOR votes on directors, auditors, and pay amid neutral sentiment but positive highlights like Piper's $1.88B adjusted revenues (+39% NI YoY). Financial results show mixed trends: revenue declines in Beyond Meat (-15.6% YoY to $275M, margins to 2.8%), Resources Connection (-16.6% YoY Q3 to $108M), contrasted by Healthy Extracts (+45% YoY to $4.5M) and EBR Systems (Q1 implants doubled to 41). Biotech shines with IDEAYA-AstraZeneca collaboration on IDE849 for SCLC, while SPAC mergers advance (Abra-New Providence $750M deal, Einride-Legato). Institutional 13F-HR filings (11 funds) confirm heavy tech/ETF allocations (e.g., NVIDIA, Amazon tops), signaling conviction in megacaps. Capital allocation includes News Corp's $1B buyback continuation and Six Flags debt-reducing asset sale. Overall, portfolio-level revenue trends mixed (-16% avg in reporting firms), but positive catalysts in biotech/SPACs outweigh consumer weakness, favoring selective longs pre-market open.

19 high priority 31 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — April 08, 2026

This digest covers one civilian contract totaling $67,726,344 in obligations, with 0/1 defense-related awards, focused on federal construction and infrastructure. The Department of the Interior's Bureau of Reclamation awarded AMES FEDERAL CONTRACTING GROUP LLC a firm fixed price contract for the NGWSP Intake & River Pumping Plant in Farmington, NM, under full and open competition. The highest-conviction signal is neutral (strength 3/10, materiality 2/10) due to the private LLC recipient having no public parent and thus limited direct implications for public market portfolios. No bullish or bearish signals emerge, reflecting the isolated nature of this water supply facilities construction award (NAICS 237110). Key risk is high pricing risk under firm fixed price terms with $0 outlayed to date. Watch total outlayed progress and performance milestones toward the 2028-10-20 end date.

1 total filings
· daily

DHS Homeland Security Contracts — April 08, 2026

DHS awarded $135,428,645 in two civilian contracts during the period, with zero defense-related obligations, split between FEMA's $68.5 million engineering services contract to FOCUS REVISION PARTNERS LLC and ICE's $66.9 million detention services delivery order to THE GEO GROUP, INC. The dominant theme is steady civilian demand in homeland security mitigation and immigration enforcement facilities. Highest-conviction signal is bullish on THE GEO GROUP, INC. (materiality 7/10) for its full-and-open competition win signaling ongoing ICE detention needs. Both contracts carry high fixed-price execution risks, with FOCUS REVISION PARTNERS LLC already at $29 million outlayed toward a potential $118 million ceiling. Key watch item: outlay progress on THE GEO GROUP, INC.'s contract from $0 as it ramps from October 2025.

2 total filings
· daily

VA Healthcare & Services Contracts — April 08, 2026

The three VA Healthcare & Services contracts total $219,450,089 in obligations, entirely civilian with zero defense-related awards, centered on IT and computing services via the Department of Veterans Affairs' Technology Acquisition Center NJ and Veterans Benefits Administration. Salient CRGT, Inc. leads with the highest-materiality $93M obligation (potential $198M with options) for technical application platform services, delivering the strongest bullish signal at 7/10 strength due to full and open competition win and $21.8M early outlays. Greenbrier Government Solutions Inc. adds a solid bullish $61.3M SDVOSB set-aside for software maintenance, with $54.2M already outlayed signaling reliable cash flow. General Dynamics Information Technology's $65.1M award is neutral due to $60.7M subawards eroding prime retention, highlighting a key risk in passthrough exposure. Watch option exercises on Salient CRGT toward the $198M ceiling and remaining outlays across all contracts amid VA budget cycles.

3 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 08, 2026

HHS awarded $300,921,779 across three contracts in the HHS & Healthcare stream, with 0/3 defense-related, focusing on BARDA-funded biotech R&D for biothreat and antibiotic-resistant pathogens. Dominant theme is civilian biothreat preparedness via long-duration BARDA contracts to Shionogi Inc ($119M obligation) and Vedanta Biosciences ($79M obligation), signaling multi-year revenue potential in NAICS 541714 biotechnology R&D. Highest-conviction bullish signals stem from these full-and-open competition awards with options up to $481M for Shionogi and $114M for Vedanta, providing funding visibility amid $70M outlays already for Vedanta. The DLA Troop Support grant ($102M) adds neutral bulk but lacks revenue detail. Key watch item is Shionogi's $0 outlays to date and option exercises across both BARDA contracts, as no funds have flowed yet for the newest award.

3 total filings
· daily

New Federal Contractors — April 08, 2026

These 21 new federal contracts, aggregated at $1,703,423,541 total obligation over April 8, 2026, are entirely civilian with 0/21 defense-related, emphasizing HHS/BARDA biotech R&D, GSA/VA/State/Treasury IT services, and facilities support. Dominant agency themes include HHS ($198M+ across Shionogi and Vedanta), Treasury/IRS ($200M+ via two IBM awards), and VA ($219M+ via Salient CRGT, General Dynamics IT, Greenbrier). Highest-conviction bullish signal is Shionogi Inc's $119M HHS BARDA cost-plus-fixed-fee contract for biothreat antibiotics, with $481M potential over 10 years. Balanced by neutral/dated awards like Smartronix $116M GSA IT (2018-2023, negative outlays) and IBM $110M Treasury terminated in 2025. Key risk/watch: $0 outlays on 8 contracts (e.g., Shionogi, ManTech $77M), signaling near-term execution uncertainty amid CR risk for FY2026 awards.

21 total filings
· daily

Significant Contract Modifications ($10M+) — April 08, 2026

These 21 significant contract modifications totaling $1,703,423,541 in obligations are entirely civilian (0/21 defense-related), highlighting robust federal spending in biotech R&D, IT services, and facilities support outside DOD. Dominant themes include HHS/BARDA biothreat preparedness (Shionogi $119M, Vedanta $79M) and IT modernization across Treasury/IRS (IBM $110M + $90M), VA (Salient CRGT $93M), and GSA (Mantech $77M potential $910M). Highest-conviction bullish signal is Shionogi's $119M BARDA award (up to $482M options) for antibiotics R&D through 2036, signaling multi-year biotech revenue. Key risk is zero outlays on multiple high-value awards (e.g., Shionogi $119M, Mantech $77M, Deloitte $70M), exposing execution delays amid fixed-price structures.

21 total filings
· daily

Contract Deobligations Alert — April 08, 2026

This Contract Deobligations Alert covers 21 civilian contracts totaling $1,703,423,541 in obligations with 0 defense-related awards, highlighting robust civilian agency spending in HHS/BARDA biotech R&D and IT services across GSA, VA, Treasury/IRS, and State Department. Dominant sector themes include biothreat preparedness antibiotics (Shionogi $119M, Vedanta $79M) and multi-year IT modernization (Salient CRGT $93M VA, ManTech $77M GSA USSOUTHCOM cyber, IBM $90M Treasury). Highest-conviction bullish signal is Shionogi Inc's $119M HHS BARDA cost-plus-fixed-fee contract (potential $481M) for late-stage antibiotics R&D through 2036, signaling durable biotech revenue. Balanced by neutral signals on dated contracts like Smartronix's $116M GSA IT (negative -$162k outlays) and IBM's $110M terminated Treasury IT. Key risk is $0 outlays on 8 new/high-potential awards (e.g., ManTech $77M, Deloitte $70M), vulnerable to non-exercise amid CR uncertainty; watch outlay progression and option exercises for revenue conversion.

21 total filings
· daily

Contract Option Exercises — April 08, 2026

These 21 contract option exercises total $1,703,423,541 in obligations, entirely civilian agency awards with zero defense-related contracts, highlighting steady federal spending outside DOD amid a one-day snapshot from April 8, 2026. Dominant themes include HHS/BARDA biotech R&D for biothreat preparedness (e.g., Shionogi $119M, Vedanta $79M) and multi-agency IT modernization/services (IBM $200M+ across two Treasury awards, Salient CRGT $93M VA). Highest-conviction bullish signal is ManTech International's $77M GSA award (up to $910M ceiling) for USSOUTHCOM cyber IT, signaling long-term growth through 2032 despite $0 outlays to date. Key risk is execution uncertainty from $0 outlays on fresh awards like Shionogi and numerous firm-fixed-price structures exposing contractors to cost overruns.

21 total filings
· daily

Federal Professional Services Contracts — April 08, 2026

These four civilian federal professional services contracts total $346,731,554 in obligations, with zero defense-related awards, spanning Department of State, Pension Benefit Guaranty Corporation (PBGC), Department of Transportation (DOT)/Federal Railroad Administration (FRA), and Department of Homeland Security (DHS)/FEMA. The dominant theme is multi-year engineering and administrative support services under NAICS 541330 and related PSCs, with firm-fixed price structures introducing high execution risks. Highest-conviction signal is bullish for SERCO INC's $95.8M PBGC delivery order, where 58% ($55.7M) has already been outlayed shortly after award. Neutral signals dominate for the others due to limited outlays (e.g., $0 for Quality Support, Inc.) and option uncertainties. Key watch item: outlay progress and option exercises across all contracts, given high pricing risks and potential ceilings up to $599M combined.

4 total filings